Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin.
Publication
, Journal Article
Penny, CL; Quow, K; Rundle, CW; Al-Rohil, RN; Cardones, AR; Kheterpal, MK; Fresco, AI
Published in: Br J Dermatol
July 2022
Enfortumab vedotin (EV), a novel antibody-drug conjugate approved for metastatic urothelial carcinoma, causes a variety of cutaneous adverse reactions. We present two cases of bullous eruptions following treatment with EV, both demonstrating IgG deposition on direct immunofluorescence (DIF) correlating to the location of nectin-4 in the epidermis. This suggests that the IgG component of EV binding to nectin-4 in keratinocytes is likely a primary contributor to the high rates of cutaneous toxicity.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Br J Dermatol
DOI
EISSN
1365-2133
Publication Date
July 2022
Volume
187
Issue
1
Start / End Page
126 / 127
Location
England
Related Subject Headings
- Urinary Bladder Neoplasms
- Nectins
- Immunoglobulin G
- Humans
- Fluorescent Antibody Technique, Direct
- Drug Eruptions
- Dermatology & Venereal Diseases
- Cell Adhesion Molecules
- Carcinoma, Transitional Cell
- Antibodies, Monoclonal
Citation
APA
Chicago
ICMJE
MLA
NLM
Penny, C. L., Quow, K., Rundle, C. W., Al-Rohil, R. N., Cardones, A. R., Kheterpal, M. K., & Fresco, A. I. (2022). Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin. Br J Dermatol, 187(1), 126–127. https://doi.org/10.1111/bjd.21022
Penny, Caitlin L., Krystina Quow, Chandler W. Rundle, Rami N. Al-Rohil, Adela R. Cardones, Meenal K. Kheterpal, and Amber I. Fresco. “Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin.” Br J Dermatol 187, no. 1 (July 2022): 126–27. https://doi.org/10.1111/bjd.21022.
Penny CL, Quow K, Rundle CW, Al-Rohil RN, Cardones AR, Kheterpal MK, et al. Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin. Br J Dermatol. 2022 Jul;187(1):126–7.
Penny, Caitlin L., et al. “Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin.” Br J Dermatol, vol. 187, no. 1, July 2022, pp. 126–27. Pubmed, doi:10.1111/bjd.21022.
Penny CL, Quow K, Rundle CW, Al-Rohil RN, Cardones AR, Kheterpal MK, Fresco AI. Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin. Br J Dermatol. 2022 Jul;187(1):126–127.
Published In
Br J Dermatol
DOI
EISSN
1365-2133
Publication Date
July 2022
Volume
187
Issue
1
Start / End Page
126 / 127
Location
England
Related Subject Headings
- Urinary Bladder Neoplasms
- Nectins
- Immunoglobulin G
- Humans
- Fluorescent Antibody Technique, Direct
- Drug Eruptions
- Dermatology & Venereal Diseases
- Cell Adhesion Molecules
- Carcinoma, Transitional Cell
- Antibodies, Monoclonal